rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KPTI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      12 Health Care Stocks Moving In Monday's After-Market Session
      Nov 9BenzingaKPTIOVID
      12 Health Care Stocks Moving In Friday's After-Market Session
      Nov 6BenzingaKPTINKTX
      Karyopharm stock rating cut to neutral by Rodman on bankruptcy
      Nov 2Investing.comKPTI
      Karyopharm, deep in debt, to sell itself in bankruptcy

      The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.

      Nov 2Yahoo FinanceKPTI
      Karyopharm Therapeutics Files for Chapter 11 Bankruptcy and Agrees to Planned Merger with Ayrmid
      Nov 2Yahoo FinanceKPTI
      Karyopharm files for bankruptcy, plans merger with Ayrmid
      Nov 2Investing.comKPTI
      Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
      Nov 2Yahoo FinanceKPTI
      12 Health Care Stocks Moving In Thursday's Intraday Session
      Oct 22BenzingaKPTI
      Karyopharm Faces Liquidity Crisis Under Forbearance Agreement

      Detailed price information for Karyopharm Therapeut (KPTI-Q) from The Globe and Mail including charting and trades.

      Sep 12The Globe and MailKPTI
      Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

      Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.

      Sep 11Yahoo FinanceAMGNKPTI
      Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates

      Price targets on Karyopharm Therapeutics have swung sharply, with one bullish firm trimming its view from US$14 to US$11 and a more cautious house cutting from US$15 to US$3. These shifts reflect the split in analyst commentary, which now hinges on how investors weigh the myelofibrosis opportunity against the endometrial cancer setback and recent stock volatility. Read on to see how to follow this evolving narrative and what to watch as new data and regulatory decisions come through. Stay...

      Sep 4Yahoo FinanceKPTI
      Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

      On August 13, Karyopharm Therapeutics (NASDAQ:KPTI) held its second-quarter earnings call, and the story split cleanly in two. The company laid out a myelofibrosis combination therapy with data strong enough to earn an accelerated approval pathway from the FDA, alongside a cash position that funds operations only into September. A $15.8 million loan payment lands […]

      Aug 21Yahoo FinanceKPTI

      This is the newest page. Registered accounts read further back.